Two new appointments to its leadership team, will help boost KIFFIK’s clinical strategy. Healthcare development executive Rene Veloso joins as Chief Investment Officer (CIO) along with Dr Reginald (Reggie) Swift who will serve as a fractional Chief Scientific Officer (CSO).
As CIO, Rene will be responsible for securing capital investments from institutional partners that want to unlock the full potential of interstitial fluid real-time monitoring for a range of cancers and other diseases. Most recently, Rene was Senior Vice President at Locust Walk Partners, LLC where he led multiple high-profile M&A activities on behalf of biopharma clients.
Dr Reginald Swift is the CEO of Rubix Life Sciences, a leader in aptamer-based precision medicine. As a fractional CSO for KIFFIK Dr Swift will help shape clinical operations to ensure research and development activities meet the highest scientific standards. Earlier this year, KIFFIK and Rubix LS established a strategic partnership to advance next-generation ISF extraction technology.
